Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of Akkermansia muciniphila in the aspect of treating chronic pancreatitis

A technology for chronic pancreatitis and pancreatic atrophy, applied in the direction of application, medical preparations with non-active ingredients, medical preparations containing active ingredients, etc., can solve unclear problems, reduce release, broaden application fields, and relieve inflammation The effect of infiltration

Active Publication Date: 2021-06-11
JIANGNAN UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have shown that Akkermansia muciniphila has the effect of alleviating obesity, but whether Akkermansia muciniphila has a potential regulatory effect on chronic pancreatitis is still unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Akkermansia muciniphila in the aspect of treating chronic pancreatitis
  • Application of Akkermansia muciniphila in the aspect of treating chronic pancreatitis
  • Application of Akkermansia muciniphila in the aspect of treating chronic pancreatitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Embodiment 1 Akkermansia muciniphila bacterial agent preparation

[0028] Preparation of active bacterial agents: Akkermansia muciniphila BAA-835 was cultured strictly anaerobically in brain heart infusion medium supplemented with 2% (m / v) type III mucin. Centrifuge the bacterial solution in the logarithmic growth phase at 4°C and 8000g for 10 minutes, remove the supernatant, wash the bacterial sludge twice with sterile physiological saline, and resuspend the bacterial sludge in glycerol with a volume fraction of 30% (v / v) , optionally, it can be stored in a -80°C refrigerator.

[0029] Preparation of inactivated bacteria: Akkermansia muciniphila BAA-835 was cultured strictly anaerobically in brain heart infusion medium supplemented with 2% (m / v) type III mucin. Centrifuge the bacterial solution in the logarithmic growth phase at 4°C and 8000g for 10 minutes, remove the supernatant, wash the bacterial sludge twice with sterile physiological saline, and resuspend the ba...

Embodiment 2

[0031] Embodiment 2 The preparation of the medicine containing Akkermansia muciniphila

[0032] The bacterial suspension containing Akkermansia muciniphila BAA-835 living cells or inactivated cells prepared in Example 1 is mixed with the auxiliary materials to obtain a liquid preparation; optionally, compression molding is made into tablets; alternatively, the liquid The formulation is dried to obtain a powder; alternatively, the powder is used as a filling to prepare capsules.

[0033] Wherein, the pharmaceutical excipients include anti-adhesives, penetration enhancers, buffers, plasticizers, surfactants, defoamers, thickeners, clathrates, absorbents, humectants, solvents, propellants, Solvents, solubilizers, emulsifiers, colorants, pH regulators, binders, disintegrants, fillers, lubricants, wetting agents, integrating agents, osmotic pressure regulators, stabilizers, glidants, flavorings additives, preservatives, foaming agents, suspending agents, coating materials, fragran...

Embodiment 3

[0034] Example 3 Akkermansia muciniphila BAA-835 for the treatment of chronic pancreatitis

[0035] (1) Establishment of chronic pancreatitis model:

[0036] 8-week-old 20-23g female C57BL / 6J mice were randomly divided into control group (CON), inflammation model group (CAE), Akkermansia muciniphila BAA-835 live bacteria treatment group (CAE+L), Akkermansiamuciniphila BAA-835 Pasteurized inactivated bacteria treatment group (CAE+K), 8 animals in each group, provided controlled feeding conditions. The chronic pancreatitis model was induced by intraperitoneal injection of cerulein. Dissolve cerulein in normal saline, inject cerulein (50 μg / kg body weight) every hour for 6 consecutive injections, three days a week for four weeks. Mice in the CON group were given an equal volume of saline. During the modeling period, each mouse in the CAE+L group was given 5×10 3% glycerol by intragastric administration every day. 9CFU / mL of Akkermansia muciniphila live bacteria solution 200 μ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Volume fractionaaaaaaaaaa
Login to View More

Abstract

The invention discloses application of Akkermansia muciniphila in the aspect of treating chronic pancreatitis, and belongs to the application field of probiotics. The invention provides the application of an Akkermansia muciniphila BAA-835 strain in preparation of a product for treating chronic pancreatitis, and the strain can relieve pancreatic atrophy symptoms, acinus cell injury and inflammation infiltration, reduce release of proinflammatory cytokines and infiltration of macrophages, relieve pancreatic fibrosis degree in an active state or an inactive state, improve pancreatic fibrosis resistance and improve pancreatic fibrosis resistance. The compound can be used for preparing medicines, pharmaceutical compositions, functional foods and feeds for treating chronic pancreatitis, and has a wide application prospect.

Description

technical field [0001] The invention discloses the application of Akkermansia muciniphila in treating chronic pancreatitis, in particular relates to the application of Akkermansia muciniphila BAA-835 strain in treating chronic pancreatitis, and belongs to the application field of probiotics. Background technique [0002] Chronic pancreatitis is a multifactorial inflammatory pancreatic disease that can cause irreversible damage to pancreatic tissue and function. The main pathogenic factors of chronic pancreatitis are alcoholism, smoking, high-fat and high-protein diet, genetic factors and so on. At present, chronic pancreatitis affects 1 / 2000 of the world's population, and 13% of chronic pancreatitis patients will progress to pancreatic cancer, which has a serious impact on the lives of patients. The clinical manifestations of chronic pancreatitis are various, and the pathogenesis is not fully clear, so there is no effective drug for the treatment of chronic pancreatitis. T...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/741A61K47/10A61P1/18A61P29/00A23L33/135A23K10/18
CPCA61K35/741A61K47/10A61P1/18A61P29/00A23L33/135A23K10/18A23V2002/00A23V2200/30
Inventor 孙嘉黄伊雯潘礼龙任正楠
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com